Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC)

Tipranks - Wed Mar 18, 8:54AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NeurAxis, Inc. (NRXSResearch Report), Argenx Se (ARGXResearch Report) and Teladoc (TDOCResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

NeurAxis, Inc. (NRXS)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on NeurAxis, Inc. today. The company’s shares closed last Tuesday at $6.97.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 31.2% and a 55.7% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Fennec Pharmaceuticals. ;'>

NeurAxis, Inc. has an analyst consensus of Moderate Buy.

See today’s best-performing stocks on TipRanks >>

Argenx Se (ARGX)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Argenx Se. The company’s shares closed last Tuesday at $709.76.

According to TipRanks.com, Ahmad is a 2-star analyst with an average return of 0.0% and a 50.7% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Apellis Pharmaceuticals. ;'>

Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $1034.50, implying a 45.3% upside from current levels. In a report issued on March 2, H.C. Wainwright also maintained a Buy rating on the stock with a $940.00 price target.

Teladoc (TDOC)

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Teladoc today and set a price target of $8.25. The company’s shares closed last Tuesday at $5.60.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 11.8% and a 63.1% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Hims & Hers Health, and Envista Holdings. ;'>

Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $7.28, representing a 33.8% upside. In a report issued on March 10, Deutsche Bank also upgraded the stock to Buy with a $11.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.